PhotoPill Medical

Name

PhotoPill Medical

Legal name

PhotoPill Medical

Website

https://photopill-med.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Gastroenterology Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

akta.pro secondary industry

Inflammatory Bowel Disease (IBD) Care (HLAKAEAD)

Keywords

• Medical device development
• Inflammatory bowel disease
• Swallowable capsule devices
• Photobiomodulation therapy
• Gastroenterology therapeutics

Headquarters

HQ city

Moshava

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: The company is developing a disposable therapeutic capsule for IBD treatment. Revenue will be generated through sales of the IBD-Cap™ device to healthcare providers and patients. As a medical device in clinical development with FDA Breakthrough Device designation, the commercial model will follow traditional medical device reimbursement pathways.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

PhotoPill Medical develops a disposable swallowable electronic capsule that delivers Photo-Bio-Modulation treatment (PBMt) and gut microbiota modulating light protocols directly to inflamed intestinal tissue for patients with Inflammatory Bowel Disease. The flagship product, the IBD-Cap™, has received FDA Breakthrough Device designation for treating Crohn's Disease flare-ups non-responsive to other treatments, and the company also offers ProctCare™, a dedicated rectal treatment device for IBD Proctitis patients.

Product overview

PhotoPill Medical offers a portfolio of light-based therapeutic products for Inflammatory Bowel Disease (IBD) treatment. The core product is the IBD-Cap™, a personalized swallowable electronic capsule that delivers Photo-Bio-Modulation (PBM) treatment directly to intestinal inflammation sites. Additionally, the company offers ProctCare™, a dedicated rectal treatment device for proctitis patients. Both products utilize the company's proprietary PBMt technology platform, which uses specific light wavelengths (Red and Near Infrared) to modulate inflammation, promote tissue healing, and influence gut microbiota.

Differentiator

Problem solved

Functional benefit

Brands

• IBD-Cap™: FDA Breakthrough Device designated disposable swallowable electronic capsule for treating Crohn's Disease using Photo-Bio-Modulation treatment (PBMt)
• ProctCare™
• PhotoPill™

Products and services

• IBD-Cap™ A personalized disposable swallowable electronic capsule that delivers Photo-Bio-Modulation treatment (PBMt) and gut microbiota modulating light protocols to treat Crohn's Disease. The capsule is pre-programmed to deliver targeted topical PBM treatment adjusted to individual disease location and peristaltic rate, operating autonomously without requiring external equipment.
• ProctCare™ A dedicated rectal treatment device for IBD Proctitis patients, using Photo-Bio-Modulation treatment to deliver therapeutic light to inflamed rectal tissue. The device has shown pre-clinical and initial clinical efficacy in proctitis patients.

Quantifiable outcome

• Excellent pre-clinical results and initial clinical efficacy results in IBD Proctitis patients using ProctCare™ device

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and minor.

• University of Chicago Medicine - Digestive Diseases CentercoreStrategic or Co-development PartnerClinical advisory board partnership with Prof. David Rubin, Professor of Medicine at University of Chicago, Section Chief, Gastroenterology, Hepatology and Nutrition, and Co-Director of the Digestive Diseases Center. Prof. Rubin studies novel therapies for Crohn's disease and ulcerative colitis.
• Rambam Health Care Campus - Gastroenterology InstitutecoreStrategic or Co-development PartnerClinical advisory board partnership with Prof. Yehuda Chowers, Director of the Gastroenterology Institute at Rambam Health Care Campus and Associate Professor at the Rappaport Faculty of Medicine at the Technion. Prof. Chowers specializes in chronic inflammatory bowel diseases including Crohn's disease, ulcerative colitis, and radiation-induced bowel injury.
• Crohn's & Colitis Foundation of Israel (CCFI)minorStrategic or Co-development PartnerSharon Ben-Yehuda, Co-Founder, is a member of the CCFI scientific committee, connecting the company to the broader IBD patient advocacy and research community in Israel.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Regional players

• Jinshan Science & Technology: Chinese manufacturer of the OMOM capsule endoscopy system. Regional peer with established capsule GI technology and global distribution footprint.
• IntroMedic: South Korean manufacturer of capsule endoscopy systems (MiroCam). Regional peer in capsule GI technology with comparable product architecture to IBD-Cap™.

Emerging players

• Motus GI: Developer of the Pure-Vu System for colon cleansing during colonoscopy. Emerging peer in GI therapeutic device space targeting gastroenterology procedural workflow.
• Check-Cap: Developer of the C-Scan swallowable capsule for colorectal cancer screening. Emerging peer with shared swallowable capsule architecture in GI applications.
• AnX Robotica: Maker of NaviCam, a magnetically controlled capsule endoscopy system. Emerging peer in advanced capsule-based GI technologies with overlapping hardware complexity.

Broad incumbents

• Thor Photomedicine: Leading manufacturer of photobiomodulation (PBMt / LLLT) devices used in pain management, wound healing, and inflammation. Broad incumbent in the underlying PBMt technology that PhotoPill applies to IBD.
• Olympus Medical: Global leader in GI endoscopy equipment and therapeutic devices. Broad incumbent in gastroenterology with deep hospital relationships and established reimbursement infrastructure that any capsule-based therapy must compete against.
• Pentax Medical (HOYA): Major manufacturer of GI endoscopic instruments and therapeutic devices. Broad incumbent competing in gastroenterology clinical workflows with similar physician customer base.

Direct peers

• Given Imaging (Medtronic): Pioneer of capsule endoscopy with the PillCam platform (acquired by Covidien/Medtronic). Most direct peer given shared swallowable capsule technology in the GI space, and former employer of PhotoPill's R&D leader Semion Khait.
• CapsoVision: Developer of the CapsoCam SV-3, a 360° panoramic capsule endoscopy system. Direct peer in swallowable capsule-based GI diagnostic and therapeutic devices.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/photopill-medical

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PhotoPill Medical